Technology partnering
We are an experienced LNP and RNA technology company dedicated to professionally partnering with pharma and biotech with an established interest in nucleic acid therapeutics or vaccines. Our expert team supports start-up, early-stage, and late-stage projects by using our proprietary platforms across RNA chemistry, LNP formulation, and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners.
Flexible partnership
- Support from design, candidate designation, clinical development to regulatory approval
- From single indications to comprehensive pipeline development
Expert development
- Dedicated teams committed to meeting your project deadlines
- Seamless transition through all development
stages
Integrated offering
- In-house in-depth chemistry, formulation and manufacturing expertise
- Single resource for accelerated delivery,
no need for multiple partners
Comprehensive range of
technology platforms
We offer partnering around LNP formulation and mRNA chemistry.
- Innovative, differentiated lipid formulations enable targeted delivery and tailored biodistribution with preclinical demonstration of superiority to competing LNP. Platforms contain lipid formulations with immune activating, silent, and suppressing characteristics.
- Differentiated and tailored mRNA capabilities to achieve optimal protein expression: sequence optimization, UTR screening, optimized IVT & purification processes leading to highly expressing, ultra-pure RNA.
- Co-development of customized LNPs for a specific payload and application combining etherna’s expertise, suite of experimental tools, and proprietary ionizable lipid libraries with your disease and target knowledge.
To drive discovery and solve challenges for our partners, enabling them to deliver cost-effective,
differentiated, and efficacious RNA therapeutics.
“I’m very happy to let you know that the FDA informed us that our IND was cleared! We do expect non-hold questions in the next few weeks. We thank you so much for your great contribution!”
Versameb“etherna’s eGFP gives 3x higher expression than all others previously tested”
Karolinska Institute“I am writing to you following the experiments we performed using the GFP mRNA received from eTheRNA….. we found it to be an excellent cargo in-vitro in comparison to others”
Dan Peer“….we have now conducted our investigational experiments and I can confirm that your mRNA performed wonderfully!”
Scripps“…It has certainly been a very pleasant experience so far…”
Diosynvax“I have very much enjoyed working with the team at eTheRNA. I’ve been impressed with the quality of the work and the responsiveness of the team” – etherna’s mRNA is superior to that of Aldevron
HDT BioContact us with any queries or for pricing information.